Breathe Well Live Well
fox4kc.com |
More insurers covering first non-drug treatment for severe asthma
fox4kc.com OVERLAND PARK, Kan. — The first non-drug treatment for severe asthma has been available for five years, but it's only recently that patients have started having success in getting insurers to cover the procedure that costs more than $20,000. Michelle … |
View full post on asthma – Google News
|
Global Nebulizers, Inhalers and Respirators for Asthma Treatment Market …
Medgadget.com (blog) Asthma is a chronic inflammatory lung disease which affects persons across all ages. It creates inflammation inside the walls of airways, causing airways to narrow, swell and produce extra mucous. It is caused due to genetic factors or environmental … |
View full post on asthma – Google News
Lung Disease News |
Breo Ellipta Now Approved as Asthma Treatment for Adult Patients in Canada
Lung Disease News GlaxoSmithKline (GSK) and VIBATIV® (telavancin) developer Theravance Biopharma, have just been granted Canadian approval for Breo Ellipta, a once-a-day maintenance treatment for asthma in patients who are at least 18 years old and have reversible … |
View full post on asthma – Google News
Lung Disease News |
Tiotropium Therapy Shown As Safe and Effective Treatment for Adolescents with …
Lung Disease News Asthma is a common chronic inflammatory lung disease characterized by airflow obstruction that causes wheezing, shortness of breath, chest tightness and coughing. The respiratory disorder is estimated to affect 27 million individuals in the United States. |
View full post on asthma – Google News
|
GSK Gets Canadian Approval For BREO ELLIPTA For Treatment Of Asthma In Adults
Nasdaq BREO® ELLIPTA is a fixed-dose combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2-agonist vilanterol. Two strengths, 100/25 mcg and 200/25 mcg, have been approved in Canada for use in asthma. BREO is administered … GSK-Theravance's Breo Ellipta gets Canadian approval to treat asthma in adults GSK Receives Approval for BREO(R) ELLIPTA(R) for the Treatment of Adults With … |
View full post on asthma – Google News
|
GSK Gets Canadian Approval for BREO ELLIPTA for Treatment of Asthma in Adults
RTT News GlaxoSmithKline plc (GSK) and Theravance, Inc. (THRX) on Thursday announced the approval in Canada of BREO ELLIPTA for the once-daily maintenance treatment of asthma in patients aged 18 years and older with reversible obstructive airways disease. GSK Receives Approval for BREO(R) ELLIPTA(R) for the Treatment of Adults With … |
View full post on asthma – Google News
|
Asthma Treatment Drugs Markets in China
PR Newswire (press release) NEW YORK, Aug. 5, 2015 /PRNewswire/ — China's demand for Asthma Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed … |
View full post on asthma – Google News
The Wiire (blog) |
Ajanta Pharma bags USFDA nod For Asthma Treatment Pill
The Wiire (blog) Drug giant Ajanta Pharma has bagged final nods from the US health watchdog for generic montelukast pills and oral granules utilized for deterrence as well as cure of asthma and to ease indications of seasonal pollinosis. Ajanta Pharma Gets US Regulator's Nod for Asthma Treatment Drug Ajanta Pharma Receives Approval From USFDA For Asthma Treatment Drug |
View full post on asthma – Google News
|
Ajanta Pharma gets USFDA nod for generic asthma treatment drug
Economic Times NEW DELHI: Drug firm Ajanta Pharma has received final approvals from the US health regulator for generic montelukast tablets and oral granules used for prevention and treatment of asthma and to relieve symptoms of seasonal hay fever. The company has … |
View full post on asthma – Google News
|
BRIEF-Vectura says had pre-IND meeting with FDA on asthma treatment for …
Reuters BRIEF-Vectura says had pre-IND meeting with FDA on asthma treatment for children. July 28. July 28 Vectura Group Plc. * Announces successful pre-ind meeting with US FDA regarding vr647. * Fda has agreed with our intent to rely on 505(B) pathway for … |
View full post on asthma – Google News